drugset / Trial / NCT01336686
Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of the study is to evaluate the safety and effectiveness of MBX-102 compared to placebo when given orally once daily for 4 weeks for the treatment of hyperuricemia in patients with gout.
Timeline
- Start
- 2011-05
- Primary completion
- 2011-11
- Completion
- 2011-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Arhalofenate | Unknown | 400 mg | Oral |
| Subject | Arhalofenate | Unknown | 600 mg | Oral |
| Background | Colchicine | Small molecule | 0.6 mg | — |